Orum Therapeutics Receives FDA Clearance For IND Of ORM-1153 In Hematologic Malignancies

Reports

3

Domains carrying it

3

First reported

24 August 2026

Latest report

24 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 24 August 2026Orum Therapeutics Receives FDA Clearance For IND Of ORM-1153 In Hematologic Malignanciesrttnews.com
2. 24 August 2026Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a ...biospace.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Adicet Bio Announces FDA Clearance of IND Application for ADI-2122 reports · 2 domains · 28 August 2026
• FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer59 reports · 51 domains · 5 September 2026
• AstraZeneca's Breast Cancer Pill Gets Approval From the FDA5 reports · 5 domains · 5 September 2026
• U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...12 reports · 12 domains · 17 August 2026
• FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory ...3 reports · 3 domains · 13 August 2026
• FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune ...11 reports · 11 domains · 1 September 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a ...biospace.com · 24 August 2026
• Orum moving CD123-targeted DAC into first-in-human testing against AMLallsci.com · 24 August 2026
• Orum Therapeutics Receives FDA Clearance For IND Of ORM-1153 In Hematologic Malignanciesrttnews.com · 24 August 2026